Asadullina, D.D.,
Gilyazova, I.R.,
Ivanova, E.A.,
Izmailova, S.M.,
Gilyazova, G.R.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2024) prognosis and difficult to treat. Despite significant advances in the treatment of ccRCC,
immune checkpoint
-inflammatory macrophage phenotype, which contributes to pathological
immune response, foam cell formation
on the remarkable potential of MSC-derived exosomes to not only suppress the inflammatory
responses of microglia
Piatnitskaia, Svetlana,
Rafikova, Guzel,
Bilyalov, Azat,
Chugunov, Svyatoslav,
Akhatov, Iskander,
Pavlov, Valentin,
Kzhyshkowska, Julia (2024) with the
immune system throughout the entire duration of implant use. The acute as well as long-term decisions
of activating the
immune response against tumor cells. Clinically used checkpoint inhibition using antibodies
Beylerli, Ozal,
Gareev, Ilgiz,
Beilerli, Aferin,
Ilyasova, Tatiana,
Shi, Huaizhang,
Sufianov, Albert (2024) –brain barrier, promotion of angiogenesis, and modulation of the
immune response post-cerebral infarction